

THE CHIRAL SYNTHESIS OF BICYCLOMYCIN


Juji YOSHIMURA,* Masanori YAMAURA, Tsuneji SUZUKI,
and Hironobu HASHIMOTO

Laboratory of Chemistry for Natural Products,
Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama 227

The optically active bicyclomycin was successfully
synthesized in 17 steps from *N,N'*-diacetyl-anhydroglycine.

On bicyclomycin¹⁾ (1) syntheses of racemic compound²⁾ and *N,N'*-dimethyl-4-desmethylened derivative³⁾ have been reported, but no synthesis of optically active one has appeared in literature. For that purpose, we have reported that *p*-methoxybenzyl group is suitable as *N*-protecting group, removable with ceric ammonium nitrate (CAN) under mild conditions⁴⁾ and that the bicyclic key intermediate⁵⁾ (7) could be obtained in 12 steps from *N,N'*-diacetyl-anhydroglycine. This paper communicates the chiral synthesis of 1 through the condensation of racemic 7 and 2,3-*o*-isopropylidene-2-*c*-methyl-L-glyceraldehyde (6).

For the synthesis of 6, 4-*o*-benzoyl-2-*o*-benzyl-2-*c*-methyl-D-erythritol⁶⁾ (2) was hydrogenolyzed to give the corresponding *o*-debenzylated product [3: mp 116-117 °C, $[\alpha]_D +26.5^\circ$ (*c* 1.0, MeOH)] which was converted into the corresponding 1,2-*o*-isopropylidene derivative [4: mp 65-67 °C, $[\alpha]_D -4.1^\circ$ (*c* 1.1, CHCl₃)]. Treatment of 4 with catalytic sodium methoxide in methanol gave *o*-debenzoylated product (5), which was oxidized with sodium metaperiodate to give 6 [bp 50-53 °C/32 Torr, $[\alpha]_D -7.0^\circ$ (*c* 1.0, CHCl₃); $\nu_{\text{max}}^{\text{KBr}}$: 1725 cm⁻¹ (CHO); ¹H NMR (CDCl₃): δ 9.64 (s, 1 H, CHO), 4.27 and 3.75 (ABq, 2 H, *J*=9.0 Hz, CH₂), 1.47 (s, 6 H, Ip), 1.36 (s, 3 H, CMe)]. Condensation of the carbanion of 7 with 6 gave three diastereomers, among which the main product was 7,9-di-(*p*-methoxybenzyl)-7,9-diaza-1-[(1*S*,2*S*)-2,3-*o*-isopropylidene-2-methyl-1,2,3-trihydroxypropyl]-5-methylene-6-(*t*-butyldimethylsilyl)-oxy-(1*S*,6*R*)-2-oxabicyclo[4,2,2]decane-8,10-dione. [8: mp 61-63 °C (amorphous solid); $[\alpha]_D +135^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (CDCl₃): δ 7.49, 7.28, 6.68 and 6.67 (each d, 8 H, *J*=7.0 Hz, aromatic), 6.36 (d, 1 H, OH), 5.43 and 4.87 (each bs, 2 H, methylene), 5.08 and 4.56, 4.71 and 4.37 (each ABq, *J*=15.0 and 14.0 Hz, 2 x CH₂ in MBn), 4.63 (d, 1 H, *J*=9.5 Hz, H-11), 4.05 and 3.76 (ABq, 2 H, *J*=8.5 Hz, H-13), 3.79 (s, 6 H, 2 x OMe), 3.6-3.25 and 3.05-2.80 (m, 2 H, H-3), 1.85-1.65 (m, 2 H, H-4), 1.41 and 1.36 (each s, 6 H, Ip), 1.27 (s, 3 H, CMe), 0.96 (s, 9 H, *t*-Bu), 0.46 and 0.28 (each s, 6 H, 2 x Me in TBS), ¹³C NMR: ppm 168.5 and 167.3 (each s, C-8 and C-10), 159.2, 158.9, 128.3 and 127.1 (each s, 4 x quarternary in MBn) 132.8, 130.6, 113.4 and 113.2 (each d, 4 x tertiary in MBn), 149.3 (s, C-5), 117.4 (*t*, methylene) 110.4 (s, quarternary in Ip), 87.5 and 86.9 (each s, C-1 and C-6), 82.7 (s, C-12), 79.7 (d, C-11), 75.4 (*t*, C-13), 65.4 (*t*, C-3), 55.2 (q, 2 x OMe), 47.2 and 44.8 (each *t*, 2 x CH₂ in MBn), 34.2 (*t*, C-4), 28.1 and 26.1 (each q, 2 x



Reagents and conditions:

a) 10% Pd-C/H₂, MeOH, 1 day (96 %); b) 6.0 equiv. 2-methoxypropene/cat. PPTS (pyridinium *p*-toluenesulfonate)/acetone, -30 °C → r.t., 7 h (82%); c) cat. 1 M NaOMe/MeOH, r.t., 30 min (93%); d) 1.2 equiv. NaIO₄/MeOH-H₂O, r.t., 30 min (72%); e) 2.0 equiv. *n*-BuLi/4.0 equiv. **6**/THF, -100 °C → 0 °C, 6 h (32%); f) 4.0 equiv.

0.2 M CAN/CH₃CN-H₂O (4:1), r.t., 25 min (49%); g) 6.0 equiv. 2-methoxypropene/cat. PPTS/acetone, r.t., 12 h (99%); h) 1.5 equiv. Bu₄NF/CH₂Cl₂, 0 °C, 1.5 h (95%); i) 80% AcOH, r.t., 8 h (92%).

Me in **1p**), 27.0 (q, *t*-Bu), 21.1 (q, CMe), 19.8 (s, quaternary in TBS, -2.3 (q, 2 x MeSi)]. Treatment of **8** with CAN was accompanied with *o*-deisopropylidenation to give **9** [mp 99-100 °C (amorphous solid); [α]_D²⁵ +37.8 (c 0.9, CHCl₃)]. For prevention of rearrangement of the bicyclic skeleton⁷⁾, **9** was again *o*-isopropylidenated to give **10** [mp 81-82 °C (amorphous solid); [α]_D²⁵ +58.2° (c 1.0, CHCl₃)], and then TBS group was removed to afford **11** [mp 204 °C (decomp.); [α]_D²⁵ +71.6° (c 1.0, MeOH)]. *o*-Deisopropylidenation of **11** gave **1** [¹³C NMR: ppm 170.4 and 167.2 (each s, C-8 and C-10), 149.9 (s, C-5), 116.1 (t, methylene), 88.7 and 82.4 (each s, C-1 and C-6), 78.0 (s, C-12), 71.4 (d, C-11), 67.6 (t, C-13), 64.2 (t, C-3), 36.3 (t, C-4), 24.8 (q, CMe)], whose physical data (mp, IR, ¹H NMR, and [α]_D²⁵) were identical with those of reported.¹⁾ During the preparation of the manuscript, another total synthesis was reported [R. M. Williams, R. W. Armstrong, and J.-S. Dung, J. Am. Chem. Soc., **106**, 5749 (1984)]. The authors are grateful to Fujisawa pharmaceutical Co. for the gift of natural product.

References

- 1) T. Miyoshi, N. Miyairi, H. Aoki, M. Kohsaka, H. Sakai, and H. Imanaka, J. Antibiot., **25**, 569 (1972); T. Kamiya, S. Maeno, M. Hashimoto, and Y. Mine, *ibid.*, **25**, 576 (1972); S. Miyamura, N. Ogasawara, H. Otsuka, S. Niwayama, H. Tanaka, T. Take, T. Uchiyama, H. Ochiai, K. Abe, K. Koizumi, K. Asao, K. Mitsuki, and T. Hoshino, *ibid.*, **25**, 610 (1972).
- 2) S. Nakatsuka, K. Yamada, K. Yoshida, O. Asano, Y. Murakami, and T. Goto, Tetrahedron Lett., **24**, 5627 (1983), and references cited therein.
- 3) R. M. Williams, O. P. Anderson, R. W. Armstrong, J. Joey, H. Meyers, and C. Erikson, J. Am. Chem. Soc., **104**, 6092 (1982); R. M. Williams, J.-S. Dung, J. Joey, R. W. Armstrong, and H. Meyers, *ibid.*, **105**, 3214 (1983), and references cited therein.
- 4) J. Yoshimura, M. Yamaura, T. Suzuki, and H. Hashimoto, Chem. Lett., **1983**, 1001.
- 5) M. Yamaura, T. Suzuki, H. Hashimoto, J. Yoshimura, and C. Shin, Chem. Lett., **1984**, 1547.
- 6) J. Yoshimura, K. Hara, M. Yamaura, K. Mikami, and H. Hashimoto, Bull. Chem. Soc. Jpn., **55**, 933 (1982).
- 7) O. Wacker, W. Kump, and B. W. Müller, Tetrahedron Lett., **24**, 5607 (1983).

(Received October 19, 1984)